ANRS 0144S COVICOMPARE-GUINEE
Phase II trial evaluating the immunogenicity and safety of the BBIBP-CorV vaccine in adults in Guinea.
Last updated on 27 March 2024
Primary objective
To assess the effect of BBIBP-CorV vaccine on the humoral immune response in adults, one month after full vaccination for SARS-CoV-2.
Theme
SARS-CoV-2
Status
Ongoing study
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr
You are participating or have participated in this study
On the form above, you will find information on the ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.
If you would like to find out more about your participation in a clinical study, please see the section below.
Visit the participant area